trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Thalidomide is a potent inhibitor of angiogenesis.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
7 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Thalidomide is a potent inhibitor of angiogenesis?

Yes. Multiple peer-reviewed studies establish that thalidomide functions as a potent anti-angiogenic agent, notably through the depletion or regulation of vascular endothelial growth factor (VEGF) signaling pathways.

Verdict: SUPPORTED · 7 sources for, 0 against · Last checked

The analysis

The claim that thalidomide is a potent inhibitor of angiogenesis is directly supported by multiple retrieved papers detailing its antiangiogenic mechanism of action, downregulation of VEGF receptors, and clinical utility in angiogenesis-related conditions like hemorrhages and multiple myeloma.

Evidence for · 7
Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate
2005
Demonstrates that thalidomide induces antiangiogenic action via ceramide-mediated depletion of VEGF receptors.
Get citation
Yabu, T., Tomimoto, H., Taguchi, Y., Yamaoka, S., Igarashi, Y., & Okazaki, T. (2005). Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. doi.org. https://doi.org/10.1182/blood-2004-09-3679

See more details
More for · 6
The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design.
2026
Highlights renewed clinical investigation showing potent antiangiogenic activities of thalidomide.
Get citation
K, N., M, K., M, G., A, P., & CG, N. (2026). The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design.. doi.org. https://doi.org/10.1002/cmdc.202501105

A review of thalidomide and digestive system related diseases.
2025
Notes thalidomide's anti-angiogenic effects in treating digestive disorders and bleeding.
Get citation
Z, X., W, J., Z, L., & S, S. (2025). A review of thalidomide and digestive system related diseases.. doi.org. https://doi.org/10.3389/fonc.2025.1543757

Renaissance of Phoenix Drug Thalidomide-New Insights into Practical Clinical Application and Optimization Strategies for Managing Adverse Effects in Digestive Diseases.
2025
Describes thalidomide's re-emergence as a repurposed agent due to its anti-angiogenic properties.
Get citation
X, Y., Z, G., C, L., R, T., R, L., H, W., K, S., W, C., K, H., & D, W. (2025). Renaissance of Phoenix Drug Thalidomide-New Insights into Practical Clinical Application and Optimization Strategies for Managing Adverse Effects in Digestive Diseases.. doi.org. https://doi.org/10.3390/ph18111689

Uncovering Thalidomide Mechanism of Action: Neuropilin 1 Represents the Target of Antiangiogenic and Immunomodulatory Effect in Chronic Lymphocytic Leukemia
2011
Connects thalidomide-induced reduction of VEGF to mechanisms of antiangiogenesis.
Get citation
Giannopoulos, K., Omiotek, M., Kosior, K., Mlak, R., Kowal, M., Rolinski, J. M., Dohner, H., Stilgenbauer, S., Dmoszynska, A., & Bullinger, L. (2011). Uncovering Thalidomide Mechanism of Action: Neuropilin 1 Represents the Target of Antiangiogenic and Immunomodulatory Effect in Chronic Lymphocytic Leukemia. doi.org. https://doi.org/10.1182/blood.v118.21.4608.4608

Case report: A case of radiation-induced diffuse hemorrhagic gastroduodenitis successfully treated with thalidomide.
2026
Shows successful clinical use of thalidomide to control severe hemorrhage by leveraging its anti-angiogenic properties.
Get citation
Y, Z., L, Z., F, Z., Y, L., & N, C. (2026). Case report: A case of radiation-induced diffuse hemorrhagic gastroduodenitis successfully treated with thalidomide.. doi.org. https://doi.org/10.3389/fphar.2026.1809335

Antiangiogenic Treatment of Patients with Hereditary Hemorrhagic Telangiectasia: Experience of a Hungarian Center.
2025
Utilizes thalidomide as an antiangiogenic treatment that targets VEGF pathways in bleeding disorders.
Get citation
B, B., A, C., T, M., Z, B., R, G., G, B., S, K., P, S., Á, I., & G, P. (2025). Antiangiogenic Treatment of Patients with Hereditary Hemorrhagic Telangiectasia: Experience of a Hungarian Center.. doi.org. https://doi.org/10.3390/jcm14228160

What does the evidence say?

The claim that thalidomide is a potent inhibitor of angiogenesis is directly supported by multiple retrieved papers detailing its antiangiogenic mechanism of action, downregulation of VEGF receptors, and clinical utility in angiogenesis-related conditions like hemorrhages and multiple myeloma.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work